- Home
- GPCR vs NVCR Comparison
GPCR vs NVCR Comparison
Compare GPCR & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPCR
- NVCR
- Stock Information
- Founded
- GPCR 2016
- NVCR 2000
- Country
- GPCR United States
- NVCR Switzerland
- Employees
- GPCR N/A
- NVCR N/A
- Industry
- GPCR
- NVCR Medical/Dental Instruments
- Sector
- GPCR
- NVCR Health Care
- Exchange
- GPCR Nasdaq
- NVCR Nasdaq
- Market Cap
- GPCR 1.2B
- NVCR 1.4B
- IPO Year
- GPCR 2023
- NVCR 2015
- Fundamental
- Price
- GPCR $30.52
- NVCR $13.28
- Analyst Decision
- GPCR Strong Buy
- NVCR Buy
- Analyst Count
- GPCR 8
- NVCR 7
- Target Price
- GPCR $69.57
- NVCR $28.79
- AVG Volume (30 Days)
- GPCR 1.0M
- NVCR 1.8M
- Earning Date
- GPCR 11-12-2025
- NVCR 10-30-2025
- Dividend Yield
- GPCR N/A
- NVCR N/A
- EPS Growth
- GPCR N/A
- NVCR N/A
- EPS
- GPCR N/A
- NVCR N/A
- Revenue
- GPCR N/A
- NVCR $630,160,000.00
- Revenue This Year
- GPCR N/A
- NVCR $6.68
- Revenue Next Year
- GPCR N/A
- NVCR $7.01
- P/E Ratio
- GPCR N/A
- NVCR N/A
- Revenue Growth
- GPCR N/A
- NVCR 14.58
- 52 Week Low
- GPCR $13.22
- NVCR $10.87
- 52 Week High
- GPCR $42.57
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- GPCR 72.59
- NVCR 48.73
- Support Level
- GPCR $25.67
- NVCR $13.94
- Resistance Level
- GPCR $30.93
- NVCR $14.69
- Average True Range (ATR)
- GPCR 1.81
- NVCR 0.59
- MACD
- GPCR 0.33
- NVCR 0.00
- Stochastic Oscillator
- GPCR 94.40
- NVCR 35.36
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.